November 30th, 2009
Rehovot, Israel – November 30, 2009 – Evogene Ltd. (TASE: EVGN) announced today the successful completion of its previously announced program to substantially increase the company's R&D and administrative facilities.
During the past year, the company has developed and is now operating a new greenhouse site at Kibutz Naan, Israel for model and target plant growth. The site is comprised of 15 state of the art greenhouses with cutting edge equipment for plant validation assays. In addition, the company completed the expansion of its existing facilities in Rehovot, which included substantial increases to all computational and lab-based components of its gene discovery and plant validation platform, including molecular biology and tissue culture, in addition to new administrative offices.
Ofer Haviv, Evogene's President and CEO stated: "Since Evogene's formation in 2002, the company has established a powerful technology platform that enables highly accurate and rapid computational discovery and plant validation of candidate genes, linked to desired plant traits. During the past two years, we significantly increased our gene discovery and validation capabilities in terms of gene quantities and efficiency and entered into several new collaborations. In addition, during this time period we more than doubled the size of our technological team, which now consists of more than 80 persons from all the required scientific disciplines.” Ofer Haviv continued, “With the completion of this facilities expansion, we now have the facilities and equipment that will allow us to both support our existing collaboration agreements and provide us with the opportunity to pursue additional collaborations in the coming years.”
For more information on Evogene’s new greenhouses site and platform, please click here.
About Evogene
Evogene is a world leading developer of improved plant traits. The company’s proprietary product development platform combines state of the art computational gene discovery technology (The 'ATHLETE'), plant and field validation capabilities and unique selection systems. Evogene's current programs focus on the improvement of key plant traits, such as yield and stress tolerance, and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the agro-biotech and alternative energy industries. Evogene's headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE:EVGN). For additional information, please visit Evogene’s website at www.evogene.com.
This press release contains "forward-looking statements". These statements include words like "may," "expects," "believes," “scheduled” and "intends," and they describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Evogene Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Contact Information
Evogene:
Liat Cinamon
PR & IR Executive
E-mail: liatc@evogene.com
Tel: +972-8-931-1933
print page |
